GENE ONLINE|News &
5 FDA First-in-Class Approvals in 2026: New Mechanisms, New Modalities, New Markets
The FDA averaged 3.7% of its 26-year novel drug total annually, with historical shares surging from 2.4% in the 2000s to 5.2% in the 2020s.
Within the first five months of 2026, the U.S. Food and Drug Administration (FDA) has granted approval to five drugs that each represent the first of their kind — not incremental improvements on existing treatments, but entirely new drug classes targeting disease at mechanisms that were either previously unreachable or considered too complex to address. To put that in context, the FDA has historically approved an average of two to three first-in-class drugs per year — 2026 has already matched or exceeded that figure before the halfway point of the year. Spanning obesity, genetic hearing loss, breast cancer, hypertension, and blood cancer, these approvals collectively mark a shift in the ambition and execution of modern drug development.
Foundayo (orforglipron) — The First Oral GLP-1 with No Dietary Restrictions
On April 1, 2026, the FDA approved Foundayo (orforglipron), an oral glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly, for the treatment of obesity and overweight in adults with at least one weight-related comorbidity.
GLP-1 receptor agonists have transformed obesity and diabetes treatment in recent years, but all approved options until now required subcutaneous injection and, in the case of oral formulations, strict fasting protocols before dosing. Foundayo is a small-molecule, non-peptide GLP-1 receptor agonist — a structural distinction that allows it to be absorbed orally without food or water restrictions, taken once daily at any time.
The approval was based on data from two Phase 3 randomised, double-blind, placebo-controlled trials: ATTAIN-1 (NCT05869903) and ATTAIN-2 (NCT05872620). In ATTAIN-1, which enrolled 3,127 non-diabetic adults with obesity, participants receiving the highest dose of orforglipron achieved significantly greater body weight reduction than placebo over 72 weeks. ATTAIN-2 replicated these findings in patients with concurrent type 2 diabetes.
The clinical significance extends beyond the trial results. Analysts project Foundayo will reach $14.79 billion in annual sales by 2030, according to FactSet consensus data — in a global market where an estimated 1 billion people live with obesity, and fewer than 1 in 10 who qualify for GLP-1 therapy are currently receiving it. The pill format directly addresses the access and adherence barriers that have limited injectable GLP-1 uptake.
Otarmeni (lunsotogene parvec-cwha) — The First Gene Therapy for Genetic Hearing Loss
On April 23, 2026, the FDA granted accelerated approval to Otarmeni (lunsotogene parvec-cwha), developed by Regeneron Pharmaceuticals, making it the first gene therapy approved for genetic hearing loss and the first FDA-approved therapy to restore a neurosensory function to normal levels.
Otarmeni targets a specific form of sensorineural hearing loss caused by biallelic loss-of-function variants in the OTOF gene, which encodes otoferlin — a protein essential for synaptic vesicle fusion at the inner hair cell–auditory nerve synapse. Without functional otoferlin, sound signals cannot be transmitted from the cochlea to the auditory nerve. The therapy delivers a working copy of the OTOF gene via a single intracochlear infusion administered under general anaesthesia, using a dual adeno-associated virus (AAV) vector system to accommodate the gene’s large size.
Approval was based on results from the Phase 1/2 CHORD trial (NCT05788536), which enrolled 20 participants aged 10 months to 16 years. At 24 weeks, 80% of evaluable participants achieved clinically meaningful hearing improvement by pure tone audiometry. Among those followed to 48 weeks, all prior responders maintained their response, and 42% achieved normal hearing thresholds — defined as the ability to hear whispers.
Otarmeni was approved in 61 days following BLA submission — among the fastest review timelines in modern FDA history. Regeneron has committed to providing the therapy at no cost to clinically eligible patients in the United States, setting an unusual precedent for a gene therapy in a rare disease indication.
Continued approval is contingent upon verification of clinical benefit in the confirmatory portion of the ongoing CHORD trial.
Veppanu (vepdegestrant) — The First Approved PROTAC Therapy
On May 1, 2026, the FDA approved Veppanu (vepdegestrant), developed by Arvinas in partnership with Pfizer, for the treatment of adults with estrogen receptor-positive (ER+), HER2-negative, ESR1-mutated advanced or metastatic breast cancer following at least one prior line of endocrine therapy. The approval marks the first time a PROteolysis TArgeting Chimera (PROTAC) has received regulatory authorisation anywhere in the world.
PROTACs represent a fundamentally different approach to targeted therapy. Unlike conventional small molecules and antibodies that occupy and block a target protein’s active site, PROTACs are bifunctional molecules: one end binds the target protein, the other recruits an E3 ubiquitin ligase, directing the cell’s own proteasomal degradation machinery to destroy the target entirely. The distinction is clinically significant — degradation eliminates the protein rather than suppressing it, and because the PROTAC is released after each catalytic cycle, a single molecule can degrade multiple copies of the target protein sequentially.
Veppanu specifically degrades the oestrogen receptor (ER), which drives tumour growth in ER+ breast cancers. ESR1 mutations in the ligand-binding domain of the receptor confer resistance to standard endocrine therapies by rendering the receptor constitutively active.
The approval was supported by data from the Phase 3 VERITAC-2 trial (NCT05654623), a global, randomised, open-label study comparing vepdegestrant to fulvestrant in 624 patients with ER+/HER2- advanced breast cancer. In the 270-patient ESR1-mutant subgroup, vepdegestrant reduced the risk of disease progression or death by 43% compared to fulvestrant (hazard ratio 0.57; 95% CI: 0.42–0.77; p=0.0001), with a median progression-free survival of 5.0 months versus 2.1 months for fulvestrant.
The PROTAC platform opens access to a category of proteins long considered undruggable — those lacking a conventional binding pocket for inhibition — with implications across oncology, neurodegeneration, and inflammatory disease.
Baxfendy (baxdrostat) — The First Aldosterone Synthase Inhibitor
On May 18, 2026, the FDA approved Baxfendy (baxdrostat), developed by AstraZeneca, as the first aldosterone synthase inhibitor (ASI) approved for the treatment of hypertension — the first mechanistically new antihypertensive drug class in decades.
Hypertension affects an estimated 1.4 billion people worldwide and remains the leading modifiable cardiovascular risk factor globally. Despite the availability of multiple antihypertensive drug classes, approximately 50% of treated patients in the United States continue to have uncontrolled blood pressure, placing them at sustained risk of heart attack, stroke, and kidney disease. Existing therapies largely act downstream — blocking receptors, relaxing vessels, or reducing fluid volume — without addressing the hormonal drivers of persistent hypertension in many patients.
Baxfendy works by selectively inhibiting aldosterone synthase (CYP11B2), the enzyme responsible for the final step of aldosterone biosynthesis in the adrenal gland. By reducing aldosterone production directly, the drug targets the hormonal mechanism driving sodium retention and elevated blood pressure in patients with aldosterone-driven hypertension.
The approval was based on data from the Phase 3 BaxHTN trial (NCT06034743), a multinational, randomised, double-blind, placebo-controlled study published in the New England Journal of Medicine. In the trial, the 2 mg dose of baxdrostat reduced systolic blood pressure by 15.7 mmHg from baseline (9.8 mmHg placebo-adjusted) in patients already receiving two or more antihypertensive medications. Nearly 40% of patients on baxdrostat achieved a target systolic blood pressure below 130 mmHg, compared with 18.7% on placebo.
Beqalzi (sonrotoclax) — First China-Origin Biotech to Win a Major FDA Approval in 2026
On May 13, 2026, the FDA granted accelerated approval to Beqalzi (sonrotoclax), developed by BeOne Medicines, for the treatment of adults with relapsed or refractory mantle cell lymphoma (MCL) following at least two prior lines of systemic therapy, including a BTK inhibitor. Beqalzi is the first and only BCL-2 inhibitor approved specifically for MCL, and the first new BCL-2 inhibitor approved in the United States in a decade.
BCL-2 is an anti-apoptotic protein that cancer cells overexpress to evade programmed cell death. Sonrotoclax was designed as a next-generation BCL-2 inhibitor with greater potency and selectivity than earlier agents in the class, and a pharmacologic profile intended to improve tolerability, particularly regarding tumour lysis syndrome risk.
Efficacy was evaluated in study BGB-11417-201 (NCT05471843), a single-arm, multicentre Phase 1/2 trial enrolling 103 adults with relapsed or refractory MCL who had previously received anti-CD20-based therapy and a BTK inhibitor. The drug received FDA Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation for this indication.
The approval carries significance beyond the clinical setting. Beqalzi was approved in China before the FDA acted — a reversal of the traditional direction of drug development and regulatory precedent. BeOne Medicines, headquartered in San Carlos, California, and listed on Nasdaq, HKEX, and the Shanghai Stock Exchange, reflects a new model of global oncology development in which innovation originates in, or is co-developed with, China and subsequently earns Western regulatory approval on the basis of robust clinical data. Continued approval is contingent upon confirmation of clinical benefit in the confirmatory CELESTIAL-RRMCL trial (NCT06742996).
A Broader Signal: The Geography — and Modality — of Innovation Is Changing
Taken together, these five approvals reflect several converging trends in drug development: the maturation of gene therapy from proof-of-concept to approved medicine; the clinical validation of protein degradation as a therapeutic modality; the broadening of oral delivery to drug classes previously limited to injection; the targeting of upstream hormonal drivers rather than downstream symptoms; and the emergence of China-originated biotechs as credible contributors to the global drug approval pipeline.
Whether this pace of first-in-class approval continues through the remainder of 2026 remains to be seen. What is clear is that the scientific and regulatory infrastructure now exists to take genuinely novel mechanisms from discovery to approval — and that the geography of that innovation is expanding.
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
LATEST
EVENT
2026-08-07
Healthy Ageing Tech Show (7-9 Aug, TAIPEI WTC) (Longevity, elder care & ageing tech)
Taipei, Taiwan
2026-10-20
AusBiotech 2026 (20-23 Oct, Queensland) (Australia biotech & investment)
Queensland, Australia
